NO20075461L - Neurotrypsin inhibitorer - Google Patents

Neurotrypsin inhibitorer

Info

Publication number
NO20075461L
NO20075461L NO20075461A NO20075461A NO20075461L NO 20075461 L NO20075461 L NO 20075461L NO 20075461 A NO20075461 A NO 20075461A NO 20075461 A NO20075461 A NO 20075461A NO 20075461 L NO20075461 L NO 20075461L
Authority
NO
Norway
Prior art keywords
neurotrypsin
agrin
fragment
variant
compound
Prior art date
Application number
NO20075461A
Other languages
English (en)
Inventor
Peter Sonderegger
Stefan Hettwer
Marc F Bolliger
Birgit Dreier
Beat Kunz
Daniel Luescher
Raymond Reif
Susanne Sales
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of NO20075461L publication Critical patent/NO20075461L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/64—X and Y being nitrogen atoms, e.g. N-sulfonylguanidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976—Trypsin; Chymotrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oppfinnelsen vedrører en fremgangsmåte for å bestemme om en forbindelse er en neurotrypsinhemmer, som erat forbindelsen inkuberes sammen med neurotrypsin, en variant av det eller et fragment som omfatter proteasedomenet og med et protein eller peptid som omfatter agrin, en variant av det eller et fragment som omfatter -eller - kløyvningssetet til agrin. I en vandig bufferløsning, og mengden av kløyvning av agrin måles. I tillegg vedrører oppfinnelsen nemmere av neurotrypsin funnet ved hjelp av denne fremgangsmåte, spesielt forbindelser med formel (1) hvor Halog Haler fluor, klor eller brom, og anvendelsen av slike nemmere for behandlingen og/eller profilaksen av sykdommer forårsaket av mangel på synapser, for eksempel skjelettmuskelatrofi, schizofreni og kognitiv forstyrrelse.
NO20075461A 2005-03-30 2007-10-29 Neurotrypsin inhibitorer NO20075461L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05102481 2005-03-30
PCT/EP2006/061152 WO2006103261A2 (en) 2005-03-30 2006-03-29 Inhibitors of neurotrypsin and determination thereof

Publications (1)

Publication Number Publication Date
NO20075461L true NO20075461L (no) 2007-11-20

Family

ID=34939082

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075461A NO20075461L (no) 2005-03-30 2007-10-29 Neurotrypsin inhibitorer

Country Status (15)

Country Link
US (1) US7897364B2 (no)
EP (1) EP1868989A2 (no)
JP (1) JP4920675B2 (no)
KR (1) KR20070116932A (no)
CN (1) CN101193858B (no)
AU (1) AU2006228150B2 (no)
BR (1) BRPI0609654A2 (no)
CA (1) CA2600791A1 (no)
IL (1) IL186120A (no)
MX (1) MX2007011961A (no)
NO (1) NO20075461L (no)
NZ (1) NZ562796A (no)
RU (1) RU2424228C2 (no)
WO (1) WO2006103261A2 (no)
ZA (1) ZA200707359B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074813A2 (en) * 2006-12-21 2008-06-26 Neurotune Ag Optiogenin for the treatment of neural diseases
PL1990420T3 (pl) * 2007-05-10 2011-01-31 Neurotune Ag Sposób wykrywania aktywności neurotrypsyny in vivo, zastosowanie tego sposobu i zastosowanie C-końcowego fragmentu agryny 22 kDa jako biomarkera w diagnozowaniu i monitorowaniu zaburzeń związanych z neurotrypsyną
EP2295068A1 (en) * 2009-09-04 2011-03-16 Neurotune AG Modified agrin-fragment capable of restoring muscle strength for use as a medicament
US20130261130A1 (en) 2010-11-01 2013-10-03 Shaheen Ahmed Neurotrypsin inhibitors
US20130245064A1 (en) 2010-11-01 2013-09-19 Shaheen Ahmed Novel neurotrypsin inhibitors
EP2631657A1 (en) * 2012-02-25 2013-08-28 Neurotune AG Immunoassay for the detection of the 22kDa C-terminal fragment (CAF) of agrin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH692507A5 (de) * 1997-04-26 2002-07-15 Peter Prof Dr Sonderegger Neurotrypsin als aktive Verbindung in einem Medikament.
DE19919634C2 (de) * 1999-04-30 2001-06-07 Aventis Pharma Gmbh Test zur Bestimmung der Integrität komplexer Phospholipid/Lipid-Strukturen mit Hilfe synthetischer fluoreszenz-markierter Acylglyceride und dessen Anwendung zur Bestimmung der Aktivität von Lipasen
DE10247478A1 (de) * 2002-10-11 2004-06-24 Bioagency Ag Verfahren zur Bestimmung der enzymatischen Aktivität von Proteinen

Also Published As

Publication number Publication date
US20090170950A1 (en) 2009-07-02
IL186120A (en) 2012-08-30
WO2006103261A9 (en) 2010-05-27
NZ562796A (en) 2010-02-26
CN101193858B (zh) 2012-01-04
CA2600791A1 (en) 2006-10-05
EP1868989A2 (en) 2007-12-26
RU2007139754A (ru) 2009-05-10
US7897364B2 (en) 2011-03-01
WO2006103261A3 (en) 2007-02-22
WO2006103261A2 (en) 2006-10-05
ZA200707359B (en) 2009-08-26
MX2007011961A (es) 2008-03-14
BRPI0609654A2 (pt) 2010-04-20
KR20070116932A (ko) 2007-12-11
CN101193858A (zh) 2008-06-04
JP4920675B2 (ja) 2012-04-18
AU2006228150A1 (en) 2006-10-05
RU2424228C2 (ru) 2011-07-20
JP2008538178A (ja) 2008-10-16
AU2006228150B2 (en) 2011-09-29
IL186120A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
NO20075461L (no) Neurotrypsin inhibitorer
IS2549B (is) Kaþepsín systein próteasa hindrar
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
GEP20125683B (en) Serine proteases inhibitors for hcv infections treatment
ATE409482T1 (de) Cathepsincystein-proteasehemmer
NO20052096L (no) Fremgangsmater for a danne og screene for proteaser med endret spesifisitet.
NO20052690D0 (no) Fenylalaninderivater som dipeptidylpeptidaseinhibitorer for behandlingen eller profylaksen av sukkersyke.
CY1108146T1 (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ
NO20076554L (no) Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer
ATE553090T1 (de) Cathepsincysteinproteasehemmer
DK1680507T3 (da) Bakterieekspression af proteaseinhibitorer og varianter deraf
IS7928A (is) Sertakónasóllyfjablöndur til notkunar í leggöng
NO20081467L (no) Inhibitorer av sennproteaser
TW200631576A (en) Cathepsin cysteine protease inhibitors
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
SE0201976D0 (sv) Novel compounds
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
NO20064358L (no) Svovelforbindelser som inhibitorer for hepatitt C-virum-NS3-serinprotease
ATE331708T1 (de) Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren
DE602004019548D1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
DE602006008447D1 (de) 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren
TR201907381T4 (tr) Beta-laktamil fenilalanin, sistein ve serin vazopressin antagonisti.
NO20054169L (no) 3-(1-[3-(1,3-benzotiazol-6-yl) propylkarbamoyl]sykloalkyl]propansyrederivater som NEP-inhibitorer.
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
NO20070640L (no) Forbedrede aprotininvananter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application